

Bioethical analysis of the Brazilian primary prophylaxis protocol



Authors: Sayago M; Marques R

Affiliations: Apoio Hosp; Association of Volunteers, Reseachers and Carriers Coagulopatias

OBJECTIVES

Haemophilia is a rare disorder, without cure, and can lead to comorbidities and even dead. The treatment is factor replacement of deficient clotting factor, that in appropriate dosage, and in preventive application, can allows quality of life, without musculoskeletal injuries. Brazil, in 2014, introduced the prophylactic treatment protocol by inserting inclusion criteria, treatment regimen, and multidisciplinary monitoring. In Brazil haemophilics are treated by Single Health System (SUS). The aims of present research are to analyze bioethical issues involved in choosing and dispensing the type of treatment for hemophiliac in Brazil, through research the reality of patients, in access to treatment and quality of life.

METHODS

Were analyzed and compared based on bioethical principles, the Brazilian prophylactic treatment protocol, the guidelines of the SUS in Brazil, and the Universal Declaration of Human Rights of UNESCO.

RESULTS

The Brazilian protocol is limited to include or not the patient in treatment only by the severity of hemophilia, age and inhibitor, without regard to the patient's lifestyle and whether there will be losses in discontinuation of treatment by age. The Universal Declaration on Bioethics and Human Rights 10 as a normative framework for this research highlights that in Article 10 there is an important reference to the principle of equality: "The fundamental equality of all human beings in dignity and rights should be respected so that they are treated fairly and equitably. " This principle complements the basic ideals of universality, equity and Completeness guiding the Unified Health System of Brazil (SUS).

CONCLUSIONS

Brazilian protocol prophylaxis adequacy needs to bioethical principles compatible with UNESCO and SUS.

REFERENCES

Prophylaxis in Chidren with hemophilia: Evidence-Based Achievements, Old and New Challenges; Copolla et all